| Compound | MT-II (Melanotan II) |
|---|---|
| Category | Unapproved melanocortin agonist |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
MT-II (Melanotan II) — a unapproved melanocortin agonist — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
An unapproved alpha-MSH analog sold online for tanning and sexual effects. It has never completed drug development, and regulators have repeatedly warned against it.
Mechanism of Action
Melanotan II activates melanocortin receptors broadly, producing melanogenesis and sexual arousal effects alongside blood-pressure changes.
Research and Evidence
Early-phase studies decades ago established pharmacology; development was abandoned. No quality-controlled human trial data support cosmetic use.
Safety and Side Effects
Reported adverse events include nausea, flushing, blood-pressure elevation, new moles and — in case reports — melanoma concerns. Regulators (TGA, MHRA, others) have issued explicit warnings.
Frequently Asked Questions
What is the evidence tier of MT-II (Melanotan II)?
MT-II (Melanotan II) is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is MT-II (Melanotan II) an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for MT-II (Melanotan II)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for melanotan II studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.